Belite Bio (BLTE) Cash from Financing Activities (2024 - 2025)
Belite Bio's (BLTE) quarterly Cash from Financing Activities came in at $510.1 million in Q4 2025, up 1182.51% year-on-year from $39.8 million in Q4 2024, and up 1182.51% quarter-over-quarter from $39.8 million in Q4 2024.
Belite Bio (BLTE) Cash from Financing Activities (2024 - 2025) Analysis & Trends
Belite Bio's Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $510.1 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 15.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 510.12 Mn |
| Dec 31, 2025 | 510.12 Mn |
| Dec 31, 2024 | 39.78 Mn |
| Dec 31, 2024 | 39.78 Mn |